Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively
Alnylam Pharmaceuticals Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively increased by 0.8% to $1.33M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 2.4%, from $1.30M to $1.33M. Over 5 years (FY 2020 to FY 2025), Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively shows an upward trend with a 2.6% CAGR.
Analysis
How to read this metric
An increase often reflects the issuance of shares for employee compensation or capital raises, while a decrease reflects share buybacks.
Detailed definition
This represents the aggregate par value of all issued and outstanding common shares of the company. It reflects the foun...
Peer comparison
This is a standard line item across all public companies, though the par value per share is often nominal and varies by jurisdiction.
equity_common_stock_valueHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.19M | $1.20M | $1.20M | $1.21M | $1.21M | $1.23M | $1.24M | $1.24M | $1.25M | $1.26M | $1.26M | $1.27M | $1.28M | $1.29M | $1.29M | $1.30M | $1.31M | $1.32M | $1.32M | $1.33M |
| QoQ Change | — | +0.8% | +0.6% | +0.4% | +0.2% | +1.7% | +0.8% | +0.2% | +0.6% | +0.4% | +0.3% | +0.5% | +1.3% | +0.6% | +0.3% | +0.8% | +0.5% | +0.6% | +0.5% | +0.8% |
| YoY Change | — | — | — | — | +2.0% | +2.9% | +3.2% | +3.0% | +3.3% | +2.0% | +1.5% | +1.8% | +2.5% | +2.7% | +2.7% | +3.0% | +2.3% | +2.2% | +2.4% | +2.4% |
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively at Other Companies
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively?
- Alnylam Pharmaceuticals (ALNY) reported common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively of $1.33M in Q1 2026.
- How has Alnylam Pharmaceuticals's common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively changed year-over-year?
- Alnylam Pharmaceuticals's common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively increased by 2.4% year-over-year, from $1.30M to $1.33M.
- What is the long-term trend for Alnylam Pharmaceuticals's common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively?
- Over 5 years (2020 to 2025), Alnylam Pharmaceuticals's common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively has grown at a 2.6% compound annual growth rate (CAGR), from $1.16M to $1.32M.
- What does common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively mean?
- The total par value of all common shares currently held by investors.